Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-09

APMD vs CLYM: stock comparison and AI forecast

Apnimed, Inc. (APMD) and Climb Bio, Inc. (CLYM) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

APMD Apnimed, Inc.

Market Cap
$629M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Pharmaceutical Preparations

CLYM Climb Bio, Inc.

Price
$10.29 -13.6% · 6M
Market Cap
$591M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

APMD · CLYM

Key facts

  • APMD and CLYM have similar market capitalizations ($629M and $591M).
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricAPMDCLYM
Market Cap$629M$591M
P/B Ratio–2.59x
EPS–$-0.87
Book Value/Share–$3.97

Profitability & Margins

MetricAPMDCLYM
ROE–-26.0%
ROA–-25.1%
ROIC–-29.2%
Tax Rate–0.0%

Financial Health

MetricAPMDCLYM
Current Ratio5.19x26.58x
D/E Ratio–0.04x
Financial Leverage–1.04x
Working Capital$149M$202M

Cash Flow

MetricAPMDCLYM
Operating Cash Flow–-$53M

Income Statement

MetricAPMDCLYM
Operating Income–-$67M
Net Income–-$59M
R&D Expense–$44M

Dividend & Shareholder Information

MetricAPMDCLYM
Shares Outstanding42M57M
EPS Growth–-495.4%
FAQ

APMD vs CLYM: stock comparison and AI forecast

Which is bigger, APMD or CLYM?

APMD and CLYM have similar market capitalizations ($629M and $591M).

Which one does Intratio's AI model rank higher, APMD or CLYM?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.